Interpreting the New FDA’s 2023 Guidance Impact on Site Enablement Platforms
Stephanie Bylos2023-10-06T18:00:25-04:00Interpreting the FDA’s 2023 Guidance Impact on Site Enablement Platforms: Considerations for the Conduct of Clinical Trials of Medical Product During Major Disruptions (d/t Disasters and PHEs) Introduction In September 2023, the FDA released new guidance that supersedes the COVID-19 pandemic guidance issued in March 2020 along with the updates made to [...]